Wire · opportunities
FDA setback and probe pressure ABL Bio as pipeline progress offers rebound hope
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 September 2026 · Fusion42 review
ABL Bio faces FDA-recommended additional clinical trials for its bile duct cancer drug candidate tovetissimig delaying approval, alongside a financial probe into insider trading allegations. Despite this setback, other pipeline drugs including a gastric cancer therapy continue advancing, providing potential for recovery.
This Wire brief sits within Fusion42's coverage of Biotech, and 1 source has reported it.
◆ ◆ The Wire takeaway
Your pathway to US market for bile duct cancer drugs just got longer; plan for delays in regulatory approval and adjust your timelines accordingly. Watch ABL Bio's clinical progress closely as pipeline advances could open partnership or licensing chances despite setbacks.
◆ Coverage
1 source · 27 Sep 2026
◆ Related on Wire
◆ Topics